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Association between chronic inflammation and cancer development is exemplified by inflammatory bowel disease (IBD)
where patients with chronic uncontrolled colitis have a significantly increased risk of developing colitis-associated
colorectal cancer (CACC). CACC appears to progresses through the inflammation-dysplasia-carcinoma sequence. This
highlights the need to identify targets and interventions that reduce inflammation and prevent development of
dysplasia in the context of IBD. Using the dextran sulfate sodium (DSS) mouse model of chronic colitis and CACC, we
show that an important target of intervention in human disease would be the epithelial cell molecule MUC1 that is
aberrantly expressed on inflamed colonocytes and promotes inflammation and progression to CACC. We show that a
MUC1 vaccine can ameliorate chronic colitis and prevent development of dysplasia in the colon and thus extend survival
in human MUC1 transgenic mice. This study supports the potential of prophylactic vaccines to target antigens that
become aberrantly expressed in chronic inflammation (e.g., IBD) and continue to be expressed on the associated cancers
(e.g., colon cancer), to prevent and/or treat both diseases.
Introduction
It is well established that chronic inflammation can serve as a
carcinogenic event resulting in cancer development at the affected
site.
1 This association is exemplified in individuals with inflam-
matory bowel disease (IBD) where patients with chronic uncon-
trolled colitis have a significantly increased risk of developing
colitis-associated colorectal cancer (CACC).
2 The etiology of IBD
is unknown, but manifestations of the disease include severe
disruption in the epithelium and its associated mucus layer. The
chronically inflamed mucosa progresses through inflammation to
dysplasia to eventual adenocarcinoma.
3 This sequence suggests
that it might be possible to identify targets and interventions
directed at various stages of the disease progression. In this study
we tested the potential of an immune response, elicited through
vaccination, to reduce chronic inflammation and prevent pro-
gression to dysplasia in IBD, and thus reduce the risk of CACC.
MUC1mucinisalargeglycoproteinthatisexpressedatlowlevels
on the apical surface of ductal epithelial cells in several organs
including the colonic epithelium. Its biological functions include
lubrication and hydration of epithelia and protection against
colonization by pathogens. The extracellular domain of MUC1 is
comprised of varying number of tandem repeats region (VNTR)
composed of 20-aminoacid (HGVTSAPDTRPAPGSTAPPA) long
repeats containing five potential O-glycosylation sites that on
healthy epithelia are heavily glycosylated.
4,5 MUC1 is abnormally
expressed in all stages of the development of adenocarcinoma and in
various chronic inflammatory diseases including IBD.
6-13 Abnormal
MUC1 expression is characterized by overexpression and loss of
apical polarization. In addition, the extracellular VNTR region has
fewer carbohydrates per repeat and truncation of carbohydrate
chains exposing the peptide backbone. The mouse homolog
(Muc-1) shares only 34% homology with human MUC1in the
VNTR and thus does not play the same role in IBD and CACC as
the human MUC1 molecule. In order to study human MUC1, we
have taken advantage of the availability of human MUC1 transgenic
(MUC1.tg) mice. These mice carry the human MUC1 transgene
expressed under its own promoter and express the full-length
glycoprotein in the same spatial and tissue distribution as in
humans.
14 This includes low expression on the apical surface of
healthy epithelia and overexpression of the abnormal, hypoglyco-
sylated form on epithelial tumor cells.
We have previously shown that in the MUC1/interleukin-10
knockout (MUC1
+/IL-10
−/−) mouse model of human IBD and
CACC, derived by crossing human MUC1 transgenic mouse
(MUC1.tg) with the IL-10
−/− mouse, MUC1 expression has a
profound effect on the time of IBD occurrence, degree of
inflammation, and progression to colon cancer.
9 In addition, we
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MUC1 altered the immunosuppressive microenvironment of
chronic inflammation and led to lessening of inflammation and
protection from CACC development.
8 One of the caveats of the
spontaneous IL-10
−/− mouse model of IBD is that the time when
the inflammatory process begins varies between animals, and thus
early treatment may be prophylactic in one animal but therapeutic
in another animal. Furthermore, the lack of IL-10 makes this
model less reflective of human IBD. In the current study, we used
the dextran sulfate sodium (DSS) model of colitis where mice are
fully immunocompetent and the time of initiation of inflam-
mation can be controlled. We added to the model the human
MUC1 molecule known to be expressed in human disease but
lacking in all previous studies employing DSS. We compared
results obtained in MUC1.tg mice with those in WT mice to
confirm the importance of MUC1 in disease development and to




Human MUC1 expression accelerates colonic inflammation in
DSS-induced colitis. To induce chronic colitis, 2.5% DSS was
repeatedly administered in the drinking water to wild-type (Wt)
and MUC1.tg mice. During the course of DSS treatment, mice
were monitored for general signs of malaise, body weight loss and
diarrhea. Shortly after the first cycle of DSS, MUC1.tg mice
experienced more severe disease symptoms including greater body
weight loss compared with Wt mice. This resulted in increased
mortality in MUC1.tg mice (5 of 11) compared with Wt mice
(one of nine), with most deaths occurring at day ten after colitis
induction (Fig.1A). Colons from mice that succumbed after one
DSS treatment were examined by a pathologist. Severe colonic
inflammation and mild ulceration were found in all mice
confirming DSS water consumption and excluding dehydration
as a cause of early mortality. To establish chronic inflammation, a
second cycle of DSS was administered to surviving MUC1.tg and
Wt mice. This resulted in additional mortality in theMUC1.tg
mice (three of six) and no deaths in the Wt mice (Fig.1A). These
results suggest that in DSS-induced colitis, the expression of
human MUC1 is a contributing factor in accelerating colonic
inflammation leading to increased mortality.
Colon samples taken from MUC1.tg and Wt mice that had
received two cycles of DSS were assessed by pathologist blinded to
the sample groups. The evaluation gave significantly increased
inflammation scores for the colons from MUC1.tg compared with
Figure1. Expression of human MUC1 accelerates colonic inflammation and dysplasia in DSS-treated mice. (A) Human MUC1.tg mice (black) and Wt mice
(gray) were given two cycles of DSS in drinking water and body weight was monitored over time. (B) After two cycles of DSS, MUC1.tg and Wt mice were
sacrificed, colons removed and paraffin embedded, and stained with H&E. H&E stained colon sections were examined by pathologist and given
inflammation scores (see Materials and Methods) and assessed for dysplasia. p was determined by two-tailed unpaired t-test. (C) Representative H&E
stained colon sections showing high-grade dysplasia in MUC1.tg and no dysplasia in Wt mice. Scale bars are 100 mm.
264 OncoImmunology Volume 1 Issue 3Wt mice (Fig.1B). In addition, high grade dysplasia was found in
the colons from the MUC1.tg mice (Fig.1C, right) and none in
Wt mice (Fig.1C, left).
DSS-induced colitis increases the expression of abnormal
MUC1 in the colon. Colonic sections taken from MUC1.tg
mice after two cycles of DSS were immunostained with two
different anti-MUC1-specific monoclonal antibodies (mAb).
Antibody HMPV is MUC1 glycosylation independent and
recognizes all forms of MUC1. In contrast, antibody VU4H5
is MUC1 glycosylation dependent and recognizes only the
abnormal hypoglycosylated form of MUC1. Analysis of immuno-
stained colonic sections revealed increased expression of total
MUC1 in inflamed colons of treated mice (Fig.2A, left)
compared with untreated MUC1.tg mice with no inflammation
(Fig.2B, left). In addition, the MUC1 in treated mice was the
abnormal hypoglycosylated form (Fig.2A, right) not found in
control mice (Fig.2B, right). Higher magnification insets show
cytoplasmic MUC1 expression as well as loss of MUC1 apical
polarization in the colonic epithelial cells.
DSS-induced colitis in MUC1.tg mice results in increased
percentages of myeloid derived suppressor cells (MDSC) and
loss of CD8
+ T cells. We previously published that in the
MUC1
+/IL-10
−/− mouse model of IBD there was accumulation of
MDSC in the spleens of mice that had dysplasia and cancer.
8 We
asked whether there was a similar accumulation of MDSC in
the DSS-induced colonic inflammation and CACC. Spleen cells
isolated from MUC1.tg and Wt mice that had received two cycles
of DSS were stained for expression of Gr-1 and CD11b, cell
surface markers of mouse MDSC. Using flow cytometry we
found a statistically significant increase in the percentage of
Gr1
+CD11b
+ cells in the spleens from DSS-treated MUC1.tg
mice compared with Wt mice (Fig.2C).
Next, we examined the T-cell composition in MUC1.tg mice
with DSS-induced colitis. Isolated lymph node and spleen cells
from MUC1.tg mice that received either one or two cycles
of DSS were stained for expression of T-cell markers CD3,
CD4, and CD8. Flow cytometry revealed that after one cycle
of DSS, MUC1.tg mice experienced an increase in CD8/CD4
T-cell ratio suggesting that CD8
+ T cells were expanding in the
secondary lymphoid organs. In contrast, after two cycles of DSS
the majority of cells were CD3
+CD4
+ T cells and the CD3
+CD8
+
T cells had disappeared (Fig.2D). For comparison, a represent-
ative dot plot from MUC1.Tg mice that did not receive DSS
is shown.
This experiment recapitulates our previous results in the
MUC1
+/IL-10
−/− mouse model of colitis and suggests that
acceleration and severity of inflammation, and development of
dysplasia in the presence of human MUC1 is not unique to the
MUC1
+/IL-10
−/− model of colonic inflammation, but rather a
characteristic of MUC1
+ IBD.
Figure2. DSS-induced colitis in MUC1tg mice is characterized by increased expression of abnormal MUC1, increased percentage of MDSC and loss
of CD8
+ T cells. Immunostaining of colon tissue sections from MUC1.tg mice that received two cycles of DSS (A) and no DSS control mice (B). HMPV
antibody stains all MUC1; 4H5 antibody stains hypoglycosylated MUC1. Scale bars are 100 mm. Inserts were taken with 100x oil-immersion objective.
(C) Isolated spleen cells from Wt (n-4) and MUC1.tg (n = 4) mice were stained for Gr-1 and CD11b expression and analyzed by flow cytometry. p was
determined by two-tailed unpaired t-test. (D) Isolated spleen cells from control MUC1.tg mice that received no DSS, MUC1.tg mice that received one
cycle of DSS, and MUC1.tg mice that received two cycles of DSS were labeled for CD4 and CD8 and analyzed by flow cytometry. Representative dot plots
from two separate experiments.
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know if an immune response against the abnormal form of
MUC1 can decrease inflammation and prevent chronic inflam-
mation thus preventing development of dysplasia and progression
to CACC. Furthermore, we questioned if preexisting immune
response would prevent the loss of CD8
+ T cells observed in
MUC1.tg mice that received two cycles of DSS. As always, we
looked for any signs of autoimmunity that might result from anti-
MUC1 immunity in this particular disease setting.
The MUC1 vaccine we used to elicit anti-MUC1 immune
response was our previously published synthetic MUC1–100-mer
peptide or glycopeptide TnMUC1–100mer with E6020 adjuvant, a
synthetic, attenuated Toll-like receptor-4 agonist that promotes
both systemic and mucosal immunity.
15 The synthetic MUC1–
100-mer peptide consists of five 20-amino-acid-long tandem repeats
from the VNTR region of MUC1. The glycopeptide TnMUC1–
100merconsistsofthesamefivetandemrepeatsglycosylatedinvitro
to express the truncated tumor-associated glycan GalNAc.
16 Mice
were primedand followed bytwoboosts given two weeksapart. The
vaccine was administered nasally to promote mucosal immunity
capable of homing to the colonic mucosa.
Two weeks following the second boost, vaccinated and age-
matched MUC1.tg mice that did not receive vaccine were started
on 2.5% DSS in their drinking water. Between days four and six,
both vaccinated and unvaccinated mice experienced an average of
10% loss of their pre-DSS treatment weight (Fig.3A). Between
days six and eight, the two groups began to dramatically separate
where unvaccinated mice experienced an additional drop in
weight (15%) that required of two mice to be removed from the
protocol due to the severity of disease symptoms. In contrast,
vaccinated mice only lost an additional 5% of their pre-DSS
weight. At day ten, there was a statistically significant difference
in body weight loss between the vaccinated and unvaccinated
mice. Vaccinated mice were clearly beginning to rebound with
amelioration of disease symptoms and weight gain of 6.5% while
unvaccinated mice continued to lose body weight with an
additional three mice removed from the protocol due to severity
of disease symptoms (Fig.3B).
Vaccine induces MUC1-specific immunity. One vaccinated
MUC1.tg mouse was removed from the protocol following one
cycle of DSS to determine if the vaccine elicited a MUC1-specific
immune response. We looked for MUC1-specific CD8
+ T cells
in secondary lymphoid organs. Isolated spleen and lymph node
cells were stained with CD3, CD4, CD8 and peptide loaded
MHC class I H2K
b DimerX (BD DimerX), MHC-Ig fusion
protein that when loaded with antigen can bind to antigen-
specific T cells.
17 DimerX was incubated overnight with
either the MUC1–8mer peptide (SAPDTRPA) or glycopeptide
MUC1–10mer (SAPDTRPAPG), both derived from the VNTR
region of MUC1. The MUC1–10mer glycopeptide has the
GalNAc glycan attached to the threonine at position five.
Unloaded DimerX was used as a negative control. Using flow
cytometry, we first gated on the lower lymphocyte population in
the forward- and side-scatter plot (Fig.4A). We determined
the percentage of DimerX
+ MUC1-specific T cells by gating on
CD3
+CD8
+ T cells. We found that 49.0% of CD8
+ T cells were
specific for the MUC1–10mer glycopeptide loaded DimerX and
4.4% of CD8
+ T cells were specific for the MUC1–8mer peptide
loaded DimerX (Fig.4A). Next, we examined the larger more
granular population of cells in the forward- and side-scatter plots
(Fig.4B). The majority of cells in this gate were also CD3
+ and
almost entirely comprised of CD8
+ T cells (Fig.4B). We found
89.7% of CD3
+CD8
+ T cells were specific for the MUC1–10mer
glycopeptide loaded DimerX and 34.8% of CD8
+ T cells were
specific for the MUC1–8mer peptide loaded DimerX (Fig.4B).
This larger, more granular CD3
+CD8
+ T cell population in the
forward- and side-scatter plot is indicative of blasting T cells. We
found no DimerX
+ T cells in unvaccinated MUC1.tg mice after
one cycle of DSS (data not shown).
After two cycles of DSS isolated spleen cells were stained for
expression of Gr-1 and CD11b, MDSC cell surface markers.
Using flow cytometry, we observed difference in the percentage of
Figure3. Vaccination against abnormal MUC1 ameliorates DSS-induced weight loss. (A) Weight loss over time in vaccinated (black) and unvaccinated
(gray) MUC1.tg mice that received DSS in drinking water. (B) Percentage of original body weight in individual mice at day 10 following one cycle of DSS.
Unvaccinated MUC1.tg mice, n = 6. Vaccinated MUC1.tg mice, n = 4. p was determined by two-tailed unpaired t-test.
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with the vaccinated or unvaccinated groups. Instead, mice that
had experienced greater body weight loss during the course of
DSS treatments had increased percentage of Gr1
+CD11b
+ and
that was true for unvaccinated mice as well as vaccinated mice
(data not shown).
Lastly, after two cycles of DSS, we failed to see the high
percentage of MUC1-specific T cells that we saw after just one
cycle in vaccinated mice but they did maintain an average one to
two CD8
+/CD4
+ T cell ratio. This was in contrast to the loss of
CD8
+ T cells we found in unvaccinated MUC1.tg mice (Fig.2C).
Colonic sections taken from vaccinated and unvaccinated
MUC1.tg mice that received two cycles of DSS were immuno-
stained with anti-MUC1 antibodies HMPV and anti-MUC1
vu4H5. Analysis revealed lower level of MUC1 expression in
vaccinated compared with unvaccinated mice. Importantly,
vaccinated mice showed little or no expression of hypoglycosyl-
ated MUC1 (Fig.5, bottom right). Colon section from healthy,
unmanipulated MUC1.tg mice is shown for
comparison (Fig.2B). We found no dysplasia
in colons from vaccinated MUC1.tg mice. In
contrast, dysplasia was observed in colons from
unvaccinated MUC1.tg that received DSS.
In addition to the experimental groups we also
examined MUC1.tg and Wt mice that received
vaccine but did not receive DSS. Colons from
both groups were examined by pathologist and
no unwanted vaccine induced side effects were
found (Fig.6A). Colons from the MUC1.tg mice
were stained with both anti-MUC1 antibodies.
We found the typical low MUC1 expression with
apical polarization (Fig.6B, left) and no evidence
of abnormal hypoglycosylated MUC1 (Fig.6B,
right). In addition, we examined the T-cell com-
position in spleens and lymph nodes and found
healthy CD8
+/CD4
+ T-cell ratio with no accu-
mulation of MDSC (Fig.6C).
Discussion
We show that human MUC1 plays a pro-
inflammatory role in the establishment of chronic
colitis and CACC in the DSS mouse model of
IBD. In addition, we show that early intervention
with a MUC1vaccine can ameliorate chronic
colitis and prevent development of dysplasia in the colon and thus
extend survival in MUC1.tg mice. The vaccine is safe with no
autoimmune side effects.
We and others have shown that abnormal MUC1 expression is
not limited to fully transformed cells but can also be seen in
chronic inflammation.
8,9,11,13,18 Although we have only recently
begun to address mechanistically how MUC1 drives and
perpetuates chronic inflammation, we and others have shown
that MUC1 plays a role in tumorigenesis through changes in
intracellular signaling, adhesion and migration, and by increasing
resistance to apoptosis.
19-22 During chronic inflammation,
increased MUC1 expression is most likely due to the inflam-
matory cytokine milieu such as TNFa, IL-6, and IFNc that we
know can induce MUC1 expression in epithelial cells.
23,24
Changes in MUC1 expression could perpetuate inflammation as
we have previously shown that abnormal forms of MUC1 are
chemotactic for immature dendritic cells and this is mediated by
the epitopes in the tandem repeat region of the hypoglycosylated
Figure4. Vaccine induces MUC1-specific CD8
+ T cells.
MHC class I H2K
b DimerX (BD DimerX) was incubated
overnight with either the MUC1–8mer peptide
(SAPDTRPA) or glycopeptide MUC1–10mer (SAPD(T)
RPAPG). Isolated spleen cells from vaccinated MUC1.tg
mouse that received one cycle of DSS were stained for
expression of CD3, CD4 and CD8, mixed with peptide-
loaded DimerX and analyzed by flow cytometry. (A)
Gated on the small CD3
+CD8
+ lymphocyte population





25 In addition, we recently reported that the tandem
repeat region of MUC1 upregulated inflammatory cytokines IL-6
and TNFa expression by binding to their promoter regions in an
NFkB p65-dependent manner.
26
Our data suggest that MUC1 vaccination induces a strong
MUC1-specific CD8
+ T-cell response. Given that we see
complete prevention of dysplasia and
less hypoglycosylated MUC1 on the
epithelia of vaccinated animals, we
propose that the MUC1-specific CD8
+
T cells can target and eliminate dys-
plastic epithelial cells that are expressing
abnormal MUC1. This will prevent
tumor formation and most likely alter
the cytokine milieu resulting in an
amelioration of colonic inflammation.
Given the established association
between chronic inflammation and can-
cer, we can consider early stages of chronic inflammation as a
premalignant condition. Molecules, such as MUC1, that are
abnormally expressed in both chronically inflamed tissues and the
cancers that arise from those tissues, are most likely playing significant
roles in both diseases. As such, they can be used as targets for
immunotherapy for chronic inflammation and cancer prevention.
Figure6. MUC1 vaccine does not induce autoimmunity. (A) Representative H&E stained colon tissue sections from vaccinated MUC1.tg and Wt mice.
(B) Representative immunostaining of colon tissue sections from vaccinated MUC1.tg mice. HMPV antibody stains all MUC1; 4H5 antibody stains
hypoglycosylated MUC1. Scale bars are 100 mm. (C) Isolated spleen cells from vaccinated MUC1.tg and Wt mice were stained for expression of CD3, CD4,
CD8, Gr1, CD11b. Representative dot plots show percentage of CD4
+ and CD8
+ T cells (left panel) from the gated CD3
+ cells and the percentage of
Gr1
+CD11b
+ MDSC cells (right panel) from the gated non-CD3
+ cells.
Figure5. Vaccination results in elimination
of abnormal MUC1-expressing epithelial
cells. Representative immunostaining of
colon tissue sections from unvaccinated
and vaccinated MUC1.tg mice that
received DSS. HMPV antibody stains all
MUC1; 4H5 antibody stains hypoglycosy-
lated MUC1. Scale bars are 100 mm.
Inserted images were taken with 100
oil-immersion objective.
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Mice. C57BL/6 mice were purchased from the Jackson Labora-
tory. MUC1 transgenic mice were originally purchased from
Dr. S.J. Gendler (The Mayo Clinic) and are bred at the University
of Pittsburgh. Colitis was induced with DSS (M.W. = 36,000–
50,000; MP Biomedicals) in sterilized water, with each cycle
consisting of 5 d of 2.5% DSS (w/v) in the drinking water,
followed by 14 d of sterilized normal tap water. All experiments
were approved by the Institutional Animal Care and Use
Committee of the University of Pittsburgh.
Peptide synthesis and in vitro glycosylation. The TnMUC1100-
mer peptide used for immunization corresponds to five tandem
repeats of a 20-amino acid sequence HGVTSAPDTRPAPGSTAPPA
from the extracellular VNTR region of MUC1. Enzymatic
addition of GalNAc to the peptide was done using recombinant
UDP-GalNAc poplypeptide N-acetyl-galactosaminyltransferases
rGalNAc-T1 as previously described.
16 The MUC1 100-mer
peptide corresponds to five tandem repeats of the same 20-
amino acid sequence with no sugars. The MUC1–8mer and
glycopeptide MUC1–10–5GalNAc correspond to the extra-
cellular VNTR region of MUC1. The peptides were synthesized
at the University of Pittsburgh Genomics and proteomics Core
Laboratories.
Vaccine protocol. Mice in the vaccine group received 20 ml
intranasally (10 ml/nare) of 30 mg of either TnMUC1 100-mer or
MUC1–100-mer peptide mixed with 3 mg of adjuvant E6020 in
PBS. The adjuvant E6020 is a synthetic, attenuated Toll-like
receptor-4 agonist provided by Eisai Research Institute, Andover,
MA.
15
Histology and inflammation scores. Colons were removed
immediately after sacrifice, cut longitudinally, washed in cold 1X
PBS, fixed in 5% buffered formalin, and embedded in paraffin.
Sections (5 mm thick) were stained with H&E. Inflammation
scores (0–4) were determined by a pathologist who was blinded to
the experimental protocol using the criteria previously reported.
9
Briefly 100–200 separate microscopic fields were evaluated for
each mouse and graded 0 to 4. The total inflammation score for
each sample was determined by taking the sum of the fields
divided by the number of fields.
Immunohistochemistry. Tissue paraffin sections were depar-
affinized by baking overnight at 59°C. Endogenous peroxidase
activity was eliminated by treatment with 30% hydrogen peroxide
for 15 min at room temperature. Antigen retrieval was done by
microwave heating in 0.1% citrate buffer. Nonspecific binding
sites were blocked with 1% BSA. The anti-MUC1 antibody
HMPV (BD PharMingen) recognizes all forms of MUC1 by
binding to the epitope APDTR in the VNTR region in a
glycosylation-independent manner. The anti-MUC1 antibody
vu-4H5 (Santa Cruz Biotechnology) recognizes the epitope
APDTRPAP in the VNTR region of hypoglycosylated MUC1.
Staining was done by the avidin-biotin peroxidase method with a
commercial kit (Vectastain ABC kit, Vector Laboratories). Color
development was done using a 3,3'-diaminobenzidine kit (BD
PharMingen).
Microscopy and image acquisition. Histology sections were
observed using an Olympus BX40 microscope. Images were
acquired using a Leica DFC420 camera and Leica Application
Suite version 2.7.1 R1.
Flow cytometry. Isolated cells from spleens and lymph nodes
were washed and resuspended in fluorescence-activated cell
sorting buffer (2% fetal bovin serum in PBS) and plated at
0.5  10
6 to 1  10
6 per well. Surface Fc receptors were blocked
with the addition of anti-CD16 (BD Bioscience) and incubated
for 20 min. Cells were stained with anti-CD3, anti-CD4, anti-
CD8, anti-Gr-1, and anti-CD11b (BD Bioscience). DimerX
soluble dimeric mouse H2kb:Ig fusion protein (BD PharMingen)
was used according to manufacturer’s protocol to detect MUC1-
specific CD8
+ T cells. Cells were analyzed on an LSR II flow
cytometer (BD Bioscience), running FACSDiva software.
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